

Presenter & Panelist Biographies

Alireza Atri, MD, PhD

**Chief Medical Officer, Banner Research; Director, Banner Sun Health Research Institute
Sun City, Arizona, United States**

Dr. Atri is a renowned cognitive neurologist and Alzheimer's disease (AD) and Related Disorders (ARD) clinician-scientist. He is Chief Medical Officer of Banner Research (Banner Alzheimer's Institutes, Phoenix and Tucson) and Director of the Banner Sun Health Research Institute (Sun City), AZ. He serves as Associate Director of the NIA/NIH-funded Arizona Alzheimer's Disease Research Center (AZ-ADRC), Leader of the AZ-ADRC Clinical Core, and Co-Leader of the Biomarker Core; and on the part-time faculty at Brigham and Women's Hospital (BWH) and Harvard Medical School (HMS), Boston, MA, USA.

Dr. Atri holds degrees from UCLA (PhD Biomathematics), UCSF (MD) and Harvard Medical School/MIT (MMSc). He completed internship/residency at the Massachusetts General Hospital-Brigham and Women's Hospital-HMS programs. He serves as Co-Chair of a US Alzheimer's Association Clinical Practice Guideline workgroup; Chair of the Alzheimer's Disease International (ADI) Medical Scientific Advisory Panel and ADI Board member; and as a Project Arm Leader (PAL) for The Dominantly Inherited Alzheimer's Disease Trial Unit (DIAN-TU).

Regarding his personal motivation to study Alzheimer's disease, Dr. Atri recognizes multiple family members who lived with dementia, including his father, with whom he lived and provided in-home care for more than a decade: "This is difficult to deal with, even as a specialist, and that's why we need better solutions for everybody."

Randall Bateman, MD

Charles F. and Joanne Knight Distinguished Professor of Neurology;

**Director, Dominantly Inherited Alzheimer Network (DIAN) and DIAN Trials Unit (DIAN-TU),
WashU Medicine**

St. Louis, Missouri, United States

Randall Bateman, MD is the Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Dominantly Inherited Alzheimer Network (DIAN), and Director of the DIAN Trials Unit (DIAN-TU). Dr. Bateman's research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer's disease. His lab created the first high-accuracy blood test for Alzheimer's disease, which is now used clinically. His research in DIAN has provided evidence for a cascade of events beginning decades before symptom onset that leads to AD dementia, supporting the development of Alzheimer's disease prevention trials. Dr. Bateman directs the DIAN-TU, which launched the first prevention trial in families with early-onset Alzheimer's disease in 2012. The DIAN-TU trial is an advanced worldwide adaptive trial platform that tests the most advanced therapeutics targeting amyloid and tau in Alzheimer's disease. The DIAN-TU goal is to slow, stop, or reverse Alzheimer's disease. The DIAN-TU has launched three Phase 2/3 drug arms with a range of amyloid-beta targets and has now launched programs for tau-directed drugs in combination with amyloid drugs and a primary prevention trial to prevent amyloid plaques from forming.

Dr. Bateman has received a number of awards including the Potamkin Prize. He is an elected member of the National Academy of Medicine and is currently serving as the Appointed Chairman of the Research Subcommittee of the Health and Human Services NAPA Council, the Advisory Council on Alzheimer's Research, Care, and Services.

Tammie Benzinger, MD, PhD

Hugh Monroe Wilson Professor of Radiology; Professor of Neurological Surgery, WashU Medicine
St. Louis, Missouri, United States

Dr. Benzinger earned medical and doctoral degrees from the University of Chicago. She completed both her diagnostic radiology residency and neuroradiology fellowship at Washington University. Dr. Benzinger's research focuses on novel neuroimaging tools in the study of aging, neuroinflammation, Alzheimer disease (AD), and related disorders. The laboratory pioneers translational PET and MR imaging to investigate biomarkers for Alzheimer Disease. Her group also serves as the imaging core for the Knight Alzheimer Disease Research Center, and for the international studies of autosomal dominant AD, the Dominantly Inherited Alzheimer Network (DIAN) and its clinical trials unit, DIAN-TU. Dr. Benzinger co-chairs the Radiological Society of North America (RSNA) Quantitative Imaging Committee (QulC) and the American Society for Neuroradiology (ASNR) Alzheimer Disease, ARIA and Dementia Study Group.

Regarding her drive to study Alzheimer's disease, Dr. Benzinger shares, "My grandmother, Helen Smith, was diagnosed with dementia when I was in high school. In the 1980s, there was no way to make a specific diagnosis without a brain biopsy. In medical school, this motivated me to focus my research structure of beta-amyloid, which in turn led to my training in radiology. Finding ways to specifically diagnosis Alzheimer disease, and to use these tests to lead us forward in clinical trials and clinical practice, has been the main focus of my career. I am honored to participate in the DIAN and DIAN-TU studies as the Imaging Core Leader and am humbled by the dedication of our participants and their families."

Maria C. Carrillo, PhD

Chief Science Office and Medical Affairs Lead, Alzheimer's Association
Chicago, Illinois, United States

Dr. Carrillo oversees the implementation of the Alzheimer's Association's growing portfolio of research initiatives. Additionally, Dr. Carrillo is a co-principal investigator for the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), which is designed to track the long-term clinical response and safety outcomes of enrolled patients being treated with novel FDA-approved Alzheimer's therapies. Dr. Carrillo is also a co-primary investigator for the Association-funded and led US POINTER study, a lifestyle intervention trial to prevent cognitive decline and dementia. She is also a co-primary investigator on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS), which will explore the development of early-onset Alzheimer's disease and how it compares to the more common late-onset Alzheimer's variant.

Dr. Carrillo earned her PhD from Northwestern University's Institute for Neuroscience and completed a postdoctoral fellowship focused on Alzheimer's brain imaging and risk factors at Rush University Medical Center in Chicago. She holds a bachelor's degree in psychology from the University of Illinois.

Maritza Ciliberto, EdD

Boston, Massachusetts, United States

Maritza is a member of a DIAD family, a dedicated wife, and mother of three sons. She serves as a caregiver, research participant, and advocate within the DIAD community, demonstrating her commitment to advancing research and support for families affected by Alzheimer's disease. As an experienced educator and retired school principal, Maritza brings a wealth of knowledge and leadership to her roles. She is an active member of both the DIAN Steering Committee and the National Advisory Council on Aging (NACA), where she continues to contribute significantly to the field.

Meagan Cochran, MS, CGC

Director of Clinical Education, HudsonAlpha Institute for Biotechnology;
Director, Smith Family Clinic for Genomic Medicine
Huntsville, Alabama, United States

Meagan Cochran is a licensed and board-certified genetic counselor with 12 years of clinical experience. She obtained her undergraduate degree from Auburn University and her Master's degree in Genetic Counseling from the University of Alabama at Birmingham. She serves as the Director of Clinical Education at HudsonAlpha Institute for Biotechnology and the Director of the Smith Family Clinic for Genomic Medicine, a rare disease diagnostic clinic in North Alabama. Meagan has practiced clinical genetic counseling in a variety of settings including pediatrics, prenatal, adult medicine, and genomics. In her current role she also participates in clinical genomics research in pediatric rare disease and adult neurodegenerative disorders.

Nick Cochran, PhD

Faculty Investigator, HudsonAlpha Institute for Biotechnology
Huntsville, Alabama, United States

Dr. Nick Cochran obtained his undergraduate degree in 2010 from Auburn University and his PhD in neuroscience from the University of Alabama at Birmingham in 2015. He completed a postdoctoral fellowship and started his independent lab at the HudsonAlpha Institute for Biotechnology in 2021. Spurred by many family members affected by neurodegenerative diseases, throughout his career, Nick has focused on contributing to research on Alzheimer's disease and other neurodegenerative diseases. The Cochran lab uses genomics to better understand Alzheimer's disease and related dementias in two ways. First, they assess genetics for underrepresented populations for Alzheimer's disease and related dementias. Second, they use experimental approaches in the lab to better understand the biology of how the genome is involved in risk for disease.

Alisha Daniels, MD

Assistant Professor; Executive Director, Dominantly Inherited Alzheimer Network (DIAN),
WashU Medicine
St. Louis, Missouri, United States

Dr. Alisha Daniels, CCRC, ACRP-PM is an Assistant Professor and the Executive Director of the Dominantly Inherited Alzheimer Network (DIAN) at Washington University in St. Louis, a global natural history study enrolling since 2009 supported by the NIH and Alzheimer's Association. Dr. Daniels has nearly two decades of clinical research experience starting her career as a Clinical Research Assistant I at the Medical College of Wisconsin in the Division of Nephrology. Since this time her experience has spanned to clinical research coordination, management, and administration in nephrology, oncology, and neurology.

Dr. Daniels has been certified in clinical research as a CCRC since 2016 and obtained her ACRP-PM in 2019. She is a volunteer for the Association for Clinical Research Professionals (ACRP), a group dedicated to Good Clinical Research Practice certification, sitting as a Global Exam Committee Member from 2019 to 2024 and currently serving on ACRP's Academy Board of Trustees.

Lindsay Hohsfield, PhD

Research Professor, University of California, Irvine; Founder, Youngtimers
Innsbruck, Austria

Lindsay Hohsfield earned her Ph.D. in Neuroscience in 2014 and is currently working as a Research Professor at the University of California, Irvine. Lindsay's research interests have centered on developing effective therapeutic strategies for Alzheimer's disease, with an emphasis on investigating and manipulating the immune system. Lindsay's path to become an Alzheimer's researcher began at the age of 18 years old when her father was diagnosed with the disease; from that point on, she's dedicated her time and career to studying Alzheimer's disease. In 2020, she founded Youngtimers, an organization dedicated to improving the lives of individuals and families affected by DIAD through education, support, community, and research. In 2021, Youngtimers received its 501(c)3 nonprofit status. Lindsay also works with research institutes like DIAN to address research barriers within the DIAD community, including the development of fertility educational materials for potential Primary Prevention participants.

Kenneth Kosik, MD

Professor of Neuroscience, University of California Santa Barbara
Santa Barbara, California, United States

Kenneth S. Kosik is a physician scientist who held a series of academic appointments at the Harvard Medical School and achieved the rank of full professor there in 1996. In 2004, Kosik became the Harriman Professor of Neuroscience and Co-Director of the Neuroscience Research Institute at UCSB. Kosik's group was one of several labs that discovered Tau protein in Alzheimer neurofibrillary tangle and defined many of its molecular and biochemical features. His work has been instrumental in characterizing the large familial Alzheimer's disease kindreds in Colombia. He was the 2020 recipient of the Potamkin prize and an elected fellow of the AAAS. He has written *The Alzheimer's Solution: How Today's Care is Failing Millions and How We Can Do Better* and *Outsmarting Alzheimer's Disease*. His work has been featured in *The New York Times*, *The Wall Street Journal*, *The New Yorker*, the BBC, CNN, and "60 Minutes."

Jorge Llibre Guerra, MD

Assistant Professor of Neurology; Associate Clinical Core Leader, Dominantly Inherited Alzheimer Network (DIAN); Assistant Medical Director, DIAN Trials Unit (DIAN-TU), WashU Medicine
St. Louis, Missouri, United States

Dr. Jorge Llibre Guerra is a behavioral neurologist interested in global health and dementia prevention. His research focuses on gene-by-environment pathways implicated in neurodegeneration to identify novel targets to improved disease management. In 2016, he joined the Memory and Aging Center at the University of California-San Francisco and received fellowship training in Behavioral Neurology and Global Mental Health. In 2018, Dr. Llibre Guerra joined DIAN at WashU to complete post-doctoral studies in clinical trials. In his role as the Associate Director for DIAN, he aims to expand clinical trials and observational studies to individuals with familial AD. He has led significant progress to estimate the burden of neurodegenerative diseases in Hispanic populations. Recent work focuses on the influence of life course risk/protective factors on AD age at onset, cognitive decline, and biomarker rate of change.

Dr. Llibre Guerra states, "We are made of memories, thoughts, feelings, and connections, all held together by the brain structure and function. The idea that I can help protect that—help people stay themselves, longer—felt like a mission worth dedicating a life to."

Eric McDade, DO

Barbara Burton and Reuben M. Morriss III Professor;

Co-director, DIAN Trials Unit (DIAN-TU); Associate Director, DIAN, WashU Medicine
St. Louis, Missouri, United States

Eric McDade, DO is a professor of neurology at the Washington University School of Medicine in St. Louis. His research interests include the application of cerebrospinal fluid and neuroimaging measures to identify early pathology of Alzheimer's disease with the ultimate goal of identifying early markers of Alzheimer's disease progression that can be used in testing disease-modifying therapies.

Dr. McDade serves as the Co-Director of the Dominantly Inherited Alzheimer Network Trials Unit and the Clinical Core Leader of the Dominantly Inherited Alzheimer Network Observational Study, which uses a global, natural history study to develop prevention trials in dominantly inherited AD. As part of this work, he has co-lead an initiative to comprehensively study the changes of soluble tau-related biomarkers and is the Principal Investigator of the first-ever primary prevention trial in familial Alzheimer disease, which will test whether preventing the development of amyloid plaques will prevent the development of dementia in those with a genetic form of the Alzheimer's disease that leads to young-onset dementia.

Catherine Mummery, PhD

Professor of Neurology, University College London
London, United Kingdom

Dr. Mummery is a Professor of Neurology and consultant neurologist at the National Hospital for Neurology and Neurosurgery. She is chair of the NIHR Dementia Translational Research Collaboration, and Director of the NIHR UK Dementia Trials Network, building a national unified trials network for early phase clinical trials and working with the Mission to accelerate and enhance dementia translational research in novel treatments. She is Head of Clinical Trials at the Dementia Research Centre at University College London. She has been chief investigator on over 20 early phase drug trials of potential disease modifying agents in sporadic Alzheimer's disease (AD), and genetic forms of AD and frontotemporal dementia. As clinical lead for the UCL Neurogenetic Therapies Programme, she leads a programme of innovative collaboration between industry and academia to accelerate progress in genetic therapies in dementia.

Dr. Mummery's driving ambition is to ensure we not only have treatments that can alter the course of neurodegenerative diseases like Alzheimer's, but that we can deliver them promptly, safely and equitably.

Marty Reiswig

Cofounder, Youngtimers

Denver, Colorado, United States

Marty Reiswig is a long-time DIAN participant, founder of the private Facebook group for DIAD family members (DIADcommunity.com), cofounder of Youngtimers (Youngtimers.org), a proud member of the X-Men (mutants trying to save the world from Alzheimer's), and a public advocate. Marty and his wife Jaclyn live in the Denver, Colorado area with two young adult children, and would love to see you if you're ever in Colorado. Marty's father, uncle, grandfather, and countless other Reiswigs have passed with FAD due to the PSEN2 gene mutation.

Stephen Salloway, MD

Professor of Neurology and Psychiatry, Brown University
Providence, Rhode Island, United States

Dr. Salloway is an internationally recognized leader in clinical trials for the prevention and treatment of Alzheimer's disease. He received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University. He is the founding Director of the Memory and Aging Program at Butler Hospital. He is an expert on amyloid-related imaging abnormalities and its management and is a member of the Alzheimer's Disease and Related Disorders Therapeutic Work Group developing appropriate use recommendations to safely guide the clinical use of new disease-modifying treatments. He was the site PI at Butler Hospital for the DIAN-Observational Study and served as the Project Arm Leader for gantenerumab in DIAN-TU. He has published over 400 scientific articles and abstracts and edited books and lectures about the early diagnosis and prevention of Alzheimer's disease.

Dr. Salloway decided early on in his medical training that he wanted to make a difference in treating at least one major brain disease. Having experienced dementia in his own family, he is deeply moved and inspired by the dedication and courage of the DIAN participants. DIAN families have helped open a new molecular era for the diagnosis and treatment of AD.

Jennifer Yokoyama, PhD

Associate Professor, Memory and Aging Center, University of California San Francisco
San Francisco, California, United States

Dr. Jennifer Yokoyama is a geneticist and neuroscientist who is interested in understanding how variation across the genome contributes to changes in structure and function as the brain ages, and how this is related to increased vulnerability to—or protection from—neurodegeneration in diverse populations. Her lab is also developing peripheral transcriptomics as a biomarker for neurodegenerative diseases.

Dr. Yokoyama is an Associate Professor in the UCSF Department of Neurology and in Radiology & Biomedical Imaging, and the Mary Oakley Foundation Endowed Professor in Neurodegeneration. She has expertise in neurogenetics, genomics, transcriptomics, neuroimaging, statistics, bioinformatics, and clinical research of neurodegenerative disease. In addition, Dr. Yokoyama leads the UCSF Alzheimer Disease Research Center's (ADRC) Biomarker Core and is a faculty member in the Global Brain Health Institute.

Ellen Ziegemeier, MA

Clinical Research Specialist, WashU Medicine
St. Louis, Missouri, United States

Ellen Ziegemeier manages the DIAN Expanded Registry (EXR) and is the global lead for DIAN-TU/EXR outreach. She holds a master's degree in Anthropology and worked on multiple qualitative studies researching Alzheimer's disease and caregiving in the first half of her career before joining the DIAN-TU in 2013. Though originally from the St. Louis area, Ellen has lived and worked in Honduras and Guatemala and speaks and writes Spanish fluently. She particularly enjoys interacting with families and researchers from all over the world through the DIAN EXR and feels honored to work on behalf of participants and families each and every day.